ABVX vs. BHVN, HCM, CORT, RARE, MRUS, PBH, ARWR, XENE, IDYA, and FOLD
Should you be buying ABIVAX Société Anonyme stock or one of its competitors? The main competitors of ABIVAX Société Anonyme include Biohaven (BHVN), HUTCHMED (HCM), Corcept Therapeutics (CORT), Ultragenyx Pharmaceutical (RARE), Merus (MRUS), Prestige Consumer Healthcare (PBH), Arrowhead Pharmaceuticals (ARWR), Xenon Pharmaceuticals (XENE), IDEAYA Biosciences (IDYA), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and ABIVAX Société Anonyme (NASDAQ:ABVX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, community ranking, risk, institutional ownership, earnings, analyst recommendations and media sentiment.
In the previous week, Biohaven had 15 more articles in the media than ABIVAX Société Anonyme. MarketBeat recorded 18 mentions for Biohaven and 3 mentions for ABIVAX Société Anonyme. Biohaven's average media sentiment score of 1.72 beat ABIVAX Société Anonyme's score of 0.66 indicating that ABIVAX Société Anonyme is being referred to more favorably in the news media.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 47.9% of ABIVAX Société Anonyme shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Biohaven's return on equity of 0.00% beat ABIVAX Société Anonyme's return on equity.
ABIVAX Société Anonyme has lower revenue, but higher earnings than Biohaven.
Biohaven currently has a consensus target price of $51.63, suggesting a potential upside of 47.08%. ABIVAX Société Anonyme has a consensus target price of $34.20, suggesting a potential upside of 144.29%. Given Biohaven's higher possible upside, analysts clearly believe ABIVAX Société Anonyme is more favorable than Biohaven.
Biohaven received 368 more outperform votes than ABIVAX Société Anonyme when rated by MarketBeat users. However, 71.43% of users gave ABIVAX Société Anonyme an outperform vote while only 65.55% of users gave Biohaven an outperform vote.
Summary
Biohaven beats ABIVAX Société Anonyme on 7 of the 12 factors compared between the two stocks.
Get ABIVAX Société Anonyme News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABVX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ABIVAX Société Anonyme Competitors List
Related Companies and Tools
